Niraparib price in Singapore (2026)

There is no fixed public retail price for niraparib in Singapore in the sources we track (most supply is hospital- or named-patient based). Use the Bangladesh list price as the benchmark: BDT 850–BDT 1,095 (US$6.92–US$8.91) per unit, about SGD 8.855–SGD 11.41 in SGD per unit and SGD 265.65–SGD 342.22 per 30-unit month, before freight, customs duty and distributor margin.

Yes, but only through the rules of the Health Sciences Authority (HSA): Singapore is a high-income market with strict HSA registration and no national price control, so prices stay close to originator levels even for registered generics. Unregistered medicines may only be imported under HSA authorisation for a named patient. Prescription medicines must move on a valid prescription through a licensed importer, pharmacy or hospital; personal-use imports need a named-patient / compassionate-use authorisation.

We cannot confirm the registration status of every individual generic brand in Singapore. Health Sciences Authority (HSA) is the approving authority, and only products with a local product registration (or a special import authorisation) may be sold routinely. Ask your supplier for the local registration or import permit for the specific brand before you buy.

Bangladesh is a least-developed-country WTO member with a pharmaceutical patent exemption running to 2033, so local manufacturers can legally produce molecules that are still on patent elsewhere — and DGDA-registered list prices are public. That makes it the practical global floor price for on-patent targeted therapy and the benchmark used in import negotiations.

Singapore: approved. HSA approved Zejula (niraparib) tablet for first-line and recurrent monotherapy maintenance of advanced ovarian cancer (announced 29 June 2022); described as the only PARP inhibitor approved in Singapore as monotherapy for platinum-responsive advanced and recurrent ovarian cancer regardless of BRCA status